GLP-1 drugs are dominating the healthcare headlines from Medicare&#x27;s new GLP-1 Bridge demonstration project to the explosion in the number of people using them for more than just weight loss. David W. Johnson and Julie Murchinson explore the market, policy and population health implications on, “Unlocking the Healthcare Market Implications of GLP-1 Drugs,” the new episode of the 4sight Health Roundup podcast, moderated by David Burda.

Unlocking the Healthcare Market Implications of GLP-1 Drugs

4sight Health Roundup (for Healthcare Executives)

Welcome to the Foresight Health Roundup Podcast, Foresight Health's podcast series for healthcare revolutionaries. Outcomes matter, customers count, and value rules. Hello again, everyone. This is Dave Burda, News Editor at Foresight Health. It is Thursday, July 16th. This past Saturday, July 11th, I did something I wasn't planning on doing. I went on a GLP-1 drug. Zip-bound, to be exact.

My doctor prescribed it to me to treat my sleep apnea. I had no clue doctors were prescribing them for sleep apnea, but they are, and I'm now one of them. I'm also now part of what we're going to talk about on today's show, and that's the government's new GLP-1 bridge demonstration project for Medicare patients. Kind of. I'll explain when we get into it with Dave Johnson, founder and CEO of Foresight Health, and Julie Merchansen, partner at Transformation Capital.

Hi, Dave. Hi, Julie. How are you two doing this morning? Dave? Well, we're heading to our condo in West Michigan later today for the long weekend, or for a long weekend. That's our happy place, so I'm happy. All right. That's a good place to be. Thanks, Dave. Julie, how are you? I'm in San Francisco, just for a quick trip down for, you know, a bunch of digital health nerds getting together, chatting up. Actually, GLP-1s was a big topic last night, so it's beautiful down here. I've got to say, California's got it.

Yeah, yeah. Good for you. Thank you. Okay, before we talk about Medicare's new GLP-1 bridge program, let's talk about your experience with GLP-1s. Dave, do you know other people besides me who are on them, and how's it working out? Well, you know, Dave, it's hard not to know other people, and 11% of the U.S.

Unlocking the Healthcare Market Implications of GLP-1 Drugs

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Unlocking the Healthcare Market Implications of GLP-1 Drugs

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.